Intuitive Surgical, Inc. (NASDAQ:ISRG) Short Interest Up 5.2% in May

Intuitive Surgical, Inc. (NASDAQ:ISRG) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 3,650,000 shares, a growth of 5.2% from the April 30th total of 3,470,000 shares. Based on an average trading volume of 1,410,000 shares, the days-to-cover ratio is presently 2.6 days.

Insider Activity

In related news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,168,656.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the completion of the transaction, the senior vice president now owns 883 shares in the company, valued at $343,628.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $393.80, for a total value of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 40,779 shares of company stock valued at $15,862,204. 0.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds have recently bought and sold shares of the business. Jump Financial LLC raised its stake in shares of Intuitive Surgical by 37.5% during the 3rd quarter. Jump Financial LLC now owns 1,759 shares of the medical equipment provider’s stock worth $514,000 after purchasing an additional 480 shares in the last quarter. Merit Financial Group LLC increased its holdings in shares of Intuitive Surgical by 6.1% during the 3rd quarter. Merit Financial Group LLC now owns 3,643 shares of the medical equipment provider’s stock valued at $1,065,000 after acquiring an additional 208 shares during the last quarter. Kingsview Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 12.0% during the 3rd quarter. Kingsview Wealth Management LLC now owns 3,928 shares of the medical equipment provider’s stock valued at $1,148,000 after acquiring an additional 420 shares during the last quarter. Kestra Private Wealth Services LLC increased its holdings in shares of Intuitive Surgical by 11.7% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 3,767 shares of the medical equipment provider’s stock valued at $1,101,000 after acquiring an additional 395 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Intuitive Surgical by 30.5% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 12,305 shares of the medical equipment provider’s stock valued at $3,597,000 after acquiring an additional 2,873 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Up 0.4 %

Shares of ISRG stock opened at $403.86 on Tuesday. The stock has a 50-day simple moving average of $387.70 and a 200 day simple moving average of $368.13. Intuitive Surgical has a fifty-two week low of $254.85 and a fifty-two week high of $412.29. The stock has a market capitalization of $143.25 billion, a P/E ratio of 72.90, a P/E/G ratio of 5.19 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter last year, the business posted $1.00 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts anticipate that Intuitive Surgical will post 4.8 earnings per share for the current year.

Analyst Ratings Changes

ISRG has been the subject of a number of research analyst reports. Jefferies Financial Group raised their price target on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Citigroup lifted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. BTIG Research lifted their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $403.67.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.